| 
			
			 The jury delivered its unanimous verdict in Middlesex County 
			Superior Court in New Brunswick, just miles from J&J's headquarters, 
			in the case of plaintiff Ricardo Rimondi. 
 J&J, which faces some 13,000 talc-related lawsuits nationwide, 
			denies that its talc causes cancer, saying numerous studies and 
			tests by regulators worldwide have shown its talc to be safe and 
			asbestos-free.
 
 Johnson & Johnson on Wednesday also settled three other mesothelioma 
			talc cases pending in state courts in California, Oklahoma and New 
			York, Chris Panatier, a lawyer for the plaintiffs, told Reuters.
 
 Panatier declined to provide further details, citing confidentiality 
			agreements.
 
 Addressing the settlements, J&J in a statement said, "there are 
			one-off situations where settlement is reasonable."
 
 
			
			 
			J&J said it stood by the safety of its talc and would continue to 
			vigorously defend the safety of baby powder.
 
 "We do not have any organized program to settle Johnson's Baby 
			Powder cases, nor are we planning a settlement program," the company 
			said.
 
 Referring to the Rimondi verdict, J&J said the company's track 
			record in the talc litigation underscored "the decades of clinical 
			evidence and scientific studies by medical experts around the world" 
			supporting the safety of Johnson's Baby Powder.
 
 J&J shares, which had been down slightly, turned positive after the 
			jury verdict was announced and closed up 13 cents at $138.70.
 
 Lawyers for the 58-year old Rimondi could not be reached for 
			comment.
 
 Rimondi in 2016 was diagnosed with mesothelioma, a type of cancer 
			that has been linked to asbestos exposure.
 
 He and his wife sued J&J in 2017. They alleged that Rimondi's 
			lifetime exposure to Johnson's Baby Powder and Shower to Shower, 
			another powder product containing talc sold by J&J in the past, 
			caused his disease.
 
			 
			The jury returned its verdict in favor of the company after just 
			half an hour of deliberations, according to a livestream of the 
			proceedings by Courtroom View Network. 
			
            [to top of second column] | 
            
			 
			The healthcare conglomerate to date has faced 12 trials by 
			plaintiffs claiming asbestos in talc caused their mesothelioma.
 J&J has now been cleared of liability in four trials, with another 
			five resulting in hung juries and mistrials. Three juries have found 
			J&J liable, awarding a total of $172 million in damages. J&J is 
			appealing those verdicts.
 
			The majority of the 13,000 talc lawsuits against the company involve 
			ovarian cancer claims. Juries in those cases have hit the company 
			with verdicts as high as $4.69 billion.
 Some of the ovarian cancer verdicts have been overturned on appeal 
			on technical legal grounds, while the company's other appeals are 
			still pending.
 
 "It remains true that of all the talc-related verdicts against 
			Johnson & Johnson that have been through the appeals process, every 
			one has been overturned," the company said in its statement on 
			Wednesday.
 
 Plaintiffs' lawyers have more recently focused on arguing that 
			asbestos contamination in talc caused ovarian cancer and 
			mesothelioma.
 
 Reuters in December published a report detailing that the company 
			knew that the talc in its raw and finished powders sometimes tested 
			positive for small amounts of asbestos from the 1970s into the early 
			2000s - test results the company did not disclose to regulators or 
			consumers.
 
			
			 
			J&J denies the findings of the Reuters report, which it describes as 
			inaccurate and misleading. In emphasizing the safety of its baby 
			powder, the company says that repeated tests of the powder never 
			found asbestos and that it has cooperated fully and openly with the 
			U.S. Food and Drug Administration and other global regulators.
 (Reporting by Tina Bellon in New York; Editing by Bill Berkrot and 
			Noeleen Walder)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |